Most Pluvicto side effects improve within the six-week window between infusions, though some, like dry mouth, can persist longer or become cumulative over multiple treatment cycles. The drug’s radioactive component has a physical half-life of about 6.6 days, meaning over half the radiation leaves your body within two days and more than 99% is gone within roughly two weeks. Side effects tied directly to that radiation exposure typically follow a similar arc, peaking in the first week or two and then gradually fading.
That said, the timeline varies a lot depending on which side effect you’re dealing with. Here’s what to expect for the most common ones.
How Quickly the Drug Leaves Your Body
Pluvicto uses a radioactive isotope called lutetium-177, which has a physical half-life of 6.647 days. The drug itself is cleared from the bloodstream faster than that, with a biological elimination half-life of about 42 hours. In practical terms, more than half the radiation is out of your body within two days, and by two weeks, over 99% is gone. This is why the radiation safety precautions your care team gives you are relatively short-lived: keep distance from other adults for three days, avoid close contact with children, pregnant women, and pets for seven days, sleep alone for three nights, and use a separate bathroom if possible for three days.
But “radiation gone” doesn’t mean “side effects gone.” The damage radiation causes to healthy cells, particularly in your bone marrow, salivary glands, and kidneys, takes additional time to heal even after the radiation itself has cleared.
Fatigue: The Most Common Side Effect
Fatigue affects the majority of people on Pluvicto and tends to be worst in the first one to two weeks after each infusion, when radiation exposure is at its peak. For most patients, it improves enough before the next scheduled dose at week six. If fatigue becomes severe (classified as grade 3 or higher, meaning it limits your ability to care for yourself), treatment is paused until it improves. The dosing interval can be stretched from six weeks to as long as ten weeks to give your body more recovery time.
Fatigue often has a cumulative quality over multiple cycles. Many patients report that later infusions produce fatigue that is more intense or slower to resolve than earlier ones. This is partly because fatigue from Pluvicto isn’t just a radiation effect; it compounds with anemia, which tends to worsen over the course of treatment.
Blood Count Changes: Weeks to Months
Drops in blood cell counts, including anemia, low platelets, and low white blood cells, are among the most clinically significant side effects. These happen because radiation damages the bone marrow where blood cells are produced. Blood counts typically fall in the weeks following an infusion and need to recover to near-baseline levels before you can receive the next dose.
For moderate drops (grade 2), recovery often happens within the standard six-week cycle. More severe drops (grade 3 or higher) can take longer, and your oncologist will delay the next infusion until counts bounce back. If recovery takes more than four weeks beyond the scheduled dose date, treatment is permanently discontinued. In clinical trials, blood count problems led to permanent discontinuation in a notable percentage of patients: about 2.8% stopped due to anemia, 2.8% due to low platelets, and 1.3% due to low white blood cells.
Blood counts generally recover after the final infusion, but the timeline depends on how many cycles you’ve received and how deeply your marrow was suppressed. For some patients, full recovery takes several months after completing treatment.
Dry Mouth: Often Persistent
Dry mouth is one of the most common and potentially lasting side effects of Pluvicto. It occurred in 39% of patients in the VISION trial and 61% of patients in the PSMAfore trial. The salivary glands concentrate the drug because they express the same protein (PSMA) that the treatment targets on cancer cells. This means the glands absorb radiation directly, and the resulting damage can be slow to heal or, in some cases, permanent.
Most dry mouth from Pluvicto is mild to moderate. Severe cases (grade 3 or higher) are rare, occurring in under 1% of patients. Mild dry mouth often improves between cycles, but many patients notice it worsens progressively with each infusion as cumulative radiation damage builds in the salivary glands. After treatment ends, partial recovery of salivary function can continue for months, though some degree of dryness may persist long-term.
Staying well-hydrated, using saliva substitutes, and chewing sugar-free gum can help manage symptoms. Some treatment centers also recommend cooling the salivary glands with ice packs during infusion to reduce how much of the drug the glands absorb, though practices vary.
Nausea and Digestive Symptoms
Nausea, vomiting, diarrhea, and loss of appetite are common in the first few days after each infusion and typically resolve within one to two weeks. These are among the shorter-lived side effects. If digestive symptoms become severe and don’t respond to standard anti-nausea medications, treatment may be paused until they improve to a manageable level. For most patients, GI side effects are mild and predictable enough to manage at home between cycles.
Kidney Effects: A Longer Watch
The kidneys filter Pluvicto out of the body and absorb some radiation in the process. In clinical trials, kidney problems were uncommon and usually limited to mild, reversible increases in a blood marker called creatinine. However, because radiation damage to the kidneys can develop slowly, the FDA has flagged renal toxicity as a risk that may not show up for months or even years after treatment. Novartis is conducting long-term follow-up studies to better understand this delayed risk.
Your oncologist will monitor your kidney function with blood tests during and after treatment. For most patients, kidney function remains stable, but this is one reason follow-up appointments continue well after your last infusion.
What Happens When Side Effects Don’t Resolve
Pluvicto is given every six weeks for up to six cycles, and each dose is contingent on adequate recovery from the previous one. If a side effect hasn’t improved enough, your care team can extend the interval between doses to as long as ten weeks, reduce the dose by 20%, or stop treatment entirely. A delay that stretches beyond four weeks past the scheduled date triggers permanent discontinuation.
After your final cycle, most acute side effects (fatigue, nausea, blood count drops) resolve within weeks to a few months. Dry mouth and any subtle kidney effects represent the longer tail, potentially persisting for months or, for salivary gland damage, indefinitely in some patients. The severity and duration of lasting effects depend heavily on how many cycles you received and how your body responded along the way.